Swiss Re AG
F:SR9
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Swiss Re AG
F:SR9
|
CH |
|
M
|
MSCI Inc
F:3HM
|
US |
|
Sabra Health Care REIT Inc
F:SBC
|
US |
|
Basic Fit NV
F:B4F
|
NL |
|
Eight Capital Partners PLC
F:ECS0
|
UK |
|
H
|
Halliburton Co
F:HAL
|
US |
|
Rothschild & Co SCA
F:13F
|
FR |
|
London Stock Exchange Group PLC
F:LS4D
|
UK |
|
C
|
Canadian National Railway Co
F:CY2
|
CA |
|
Jefferies Financial Group Inc
NYSE:JEF
|
US |
|
Lipocine Inc
NASDAQ:LPCN
|
US |
|
A
|
Air Products and Chemicals Inc
F:AP3
|
US |
|
J
|
Jefferies Financial Group Inc
SWB:LN3
|
US |
|
I
|
Ionis Pharmaceuticals Inc
XMUN:ISI
|
US |
|
I
|
Investec PLC
XMUN:IVKA
|
UK |
|
F
|
Franklin Electric Co Inc
F:FE4
|
US |
|
P
|
Prudential PLC
XMUN:PRU
|
UK |
Wall St Price Targets
SR9 Price Targets Summary
Swiss Re AG
According to Wall Street analysts, the average 1-year price target for SR9 is 138.21 EUR with a low forecast of 120.31 EUR and a high forecast of 178.68 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is SR9's stock price target?
Price Target
138.21
EUR
According to Wall Street analysts, the average 1-year price target for SR9 is 138.21 EUR with a low forecast of 120.31 EUR and a high forecast of 178.68 EUR.
What is the Revenue forecast for Swiss Re AG?
Projected CAGR
7%
Over the last 13 years, the compound annual growth rate for Revenue has been 2%. The projected CAGR for the next 8 years is 7%.
What is the Net Income forecast for Swiss Re AG?
Projected CAGR
6%
Over the last 13 years, the compound annual growth rate for Net Income has been 1%. The projected CAGR for the next 8 years is 6%.
